SC-560

SC-560 is a selective cyclooxygenase-1 (COX-1) inhibitor, which is a type of nonsteroidal anti-inflammatory drug (NSAID). It is primarily used in research settings to study the role of COX-1 in various physiological and pathological processes.

Mechanism of Action

SC-560 selectively inhibits the enzyme cyclooxygenase-1 (COX-1), which is responsible for the conversion of arachidonic acid to prostaglandins. Prostaglandins are lipid compounds that have diverse roles in inflammation, pain, and fever. By inhibiting COX-1, SC-560 reduces the production of prostaglandins, thereby exerting anti-inflammatory and analgesic effects.

Pharmacokinetics

The pharmacokinetic profile of SC-560 has been studied in various animal models. It is known to have a high affinity for COX-1, with minimal activity against cyclooxygenase-2 (COX-2). This selectivity is important for understanding the differential roles of COX-1 and COX-2 in inflammation and other physiological processes.

Clinical Applications

While SC-560 is not used clinically, it serves as a valuable tool in research to delineate the specific contributions of COX-1 in various diseases. Studies have utilized SC-560 to explore its effects in models of cardiovascular disease, cancer, and neurodegenerative disorders.

Research Studies

Research involving SC-560 has provided insights into the role of COX-1 in platelet aggregation, gastric mucosal protection, and renal function. For instance, studies have shown that COX-1 inhibition by SC-560 can reduce platelet aggregation, which is a critical factor in the prevention of thrombotic events.

Safety and Toxicity

As with other NSAIDs, the use of SC-560 in research must consider potential side effects, such as gastrointestinal irritation and renal impairment. However, its selective inhibition of COX-1 may offer a different safety profile compared to non-selective NSAIDs.

Also see

• Cyclooxygenase
• Nonsteroidal anti-inflammatory drug
• Prostaglandin
• Selective COX-2 inhibitor